BridgeBio Oncology Therapeutics, Inc.
BBOTHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, BridgeBio Oncology Therapeutics, Inc. (BBOT) is listed under Biotechnology. The company carries a $720.0M market cap, placing it firmly in the small-cap category. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Market Cap
$720.0M
Beta
0.39
P/E (TTM)
—
P/E (Fwd)
-3.72
EPS (TTM)
$-2.27
EPS (Fwd)
$-2.41
ROE
-81.9%
ROA
-47.1%
Cash
$225.7M
Total Debt
$2.5M
Free CF
-$90.0M
52W Change
-12.2%
Annual Financials
Cash vs Debt
Where BBOT stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, BBOT finished 0.77% above its 150-day moving average ($9.11) and 7.27% below its 200-day moving average ($9.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BBOT overbought or oversold?
At the August 28, 2026 close, BBOT's RSI(14) was 47.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $225.7M in cash and $2.5M in debt, BBOT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$90.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -81.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
BBOT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BBOT.